The Equilibrium between Regulated Prices and R&D Expenditure on New Drugs

Jiantao CAO,Jin MA

DOI: https://doi.org/10.3969/j.issn.1673-324X.2015.01.006

2015-01-01

Abstract:Considering the fact that sole pricing policy on new drugs has not led to increasing RD expenditure in pharmaceutical industry with generic drugs' virtual-high prices,we attempt to solve it from the game theory perspective and price regulation. We build 2-stage game models with the government as a leader and the pharmaceutical manufacturer as a follower,discuss respectively two situations,in one of which the government considers only patients utility and in the other of which the government considers both patients utility and the manufacturer's profit,and prove that Nash equilibriums exist in the two situations. The theoretical analysis shows that the government's pricing strategies are scientific and efficient for guaranteeing patients utility optimally and promoting RD investment level feasibly. Furthermore,it is of more positive significance that the government,aiming at optimizing the social welfare,has an equal attitude toward patient utility and the pharmaceutical firm'profit. This is because the increase of RD expenditures result from whether higher price is determined on new drugs with lower price elasticity or lower price determined on the ones with extremely higher elasticity.